Literature DB >> 1992140

Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.

S Giorgi-Renault1, J Renault, P Gebel-Servolles, M Baron, C Paoletti, S Cros, M C Bissery, F Lavelle, G Atassi.   

Abstract

A series of heterocyclic quinones, 6-substituted and 6,7-disubstituted 4-(alkylamino)-5,8-quinazolinediones, have been synthesized in order to evaluate their in vitro cytotoxicity on L1210 leukemia cells. Among 14 derivatives that have been prepared and studied for the structure-activity relationship, the most potent cytotoxic compound on L1210 leukemia cells was the 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione (24). This compound has been tested with the use of a cell-image processor on MCF-7 human mammary and HBL human melanoma cell lines. The results show that compound 24 influences cell proliferation and blocks both cells lines in the S phase. In vivo antineoplastic activity of compound 24 has been demonstrated on a broad spectrum of murine experimental models, but it was found highly toxic and produced long-delayed deaths.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992140     DOI: 10.1021/jm00105a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Structure-activity relationships of some 4-quinazolylthiosemicarbazides and their triazolo derivatives.

Authors:  S Jantová; D Hudecová; K Spirková; S Stankovský
Journal:  Folia Microbiol (Praha)       Date:  1994       Impact factor: 2.099

2.  A highly green approach towards aromatic nitro group substitutions: catalyst free reactions of nitroimidazoles with carbon nucleophiles in water.

Authors:  Syed Raza Shah; Muhammad Ali; Muhammad U Anwar; Ahmed Al-Harrasi
Journal:  RSC Adv       Date:  2020-06-08       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.